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Managed care organizations, like almost everyone
involved in the health-care delivery system, are realiz-
ing that a major threat to our country’s health and
health-care costs is the American diet and the associ-
ated increased prevalence of obesity. As the articles in
this supplement illustrate, increased obesity, especially
abdominal obesity, is associated with clustering of risk
factors for diabetes and cardiovascular disease, now
referred to as cardiometabolic risk. The articles show
the high prevalence of cardiometabolic risk factors in
our managed care populations, the clustering of these
risk factors in individual members, and the increased
relative risk of diabetes and cardiovascular events that
will develop. That obesity is linked to diabetes, dysli-
pidemia, and cardiovascular disease is well accepted,
and many managed care organizations have active
disease management programs to help manage these
high-risk and high-cost populations. These programs
commonly target their populations through claims
data, both medical and pharmacy, that identify
through diagnosis codes or prescribed medications
appropriate members for the disease management pro-
grams. But, these programs all intervene after the pro-
verbial horse has left the barn. These members already
have developed diabetes or cardiovascular disease and
are experiencing high-cost events related to these dis-
eases. To fully realize our potential as managed care
organizations and our mission of “health mainte-
nance,” is it possible to successfully intervene before
the development of clinically recognized diabetes, cor-
onary artery disease, or cardiovascular disease?
The articles in this supplement discuss the clustering
of risk factors associated with abdominal obesity that
increased a person’s relative risk for developing diabe-
tes and cardiovascular disease. What can managed
care organizations do to identify their members with
cardiometabolic risk before the onset of clinical disease
to facilitate early treatment in the hopes of reducing
the development of diabetes, cardiovascular disease,
and associated costs? Unfortunately, there are no spe-
ciﬁc diagnosis codes or medication proﬁles that can
easily identify members with cardiometabolic risk
before they actually develop diabetes or experience a
cardiovascular event. As the article by Hollenbeak et
al. discusses, most managed care plans do not have
access to the metrics (i.e., weight circumference and
lab results for blood sugar and lipids) that identify this
population. Without the ability to identify these mem-
bers, enrolling them in traditional disease management
and case management is not possible. The recognition
of patients with increased cardiometabolic risk and ini-
tiation of early interventions and treatment will mostly
fall to primary care physicians. Managed care organi-
zations can help facilitate knowledge of these risk fac-
tors and the importance of treatment through provider
communications, but health plans are not normally
recognized as clinical experts. The primary responsi-
bility of the educational efforts toward primary care
physicians must come from appropriate specialty
organizations and key opinion leaders.
Despite managed care’s secondary role in the edu-
cational effort for primary care physicians, health
plans still play a critical role. Health plans develop
medical insurance products and determine beneﬁt
design, which greatly inﬂuences medical services pro-
vided. In general, health plans provide varying, but
limited, coverage for weight reduction. Most plans
presently do cover bariatric surgery for appropriately
selected morbidly obese patients. To their credit, an
increasing number of plans are presently offering
nutritional counseling for weight reduction or dis-
counts toward established commercial programs, such
as Weight Watchers, Jenny Craig, etc. Nevertheless,
the large majority of health plans continue to exclude
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weight reduction medications from coverage. There
are many historical reasons for the exclusion of weight
reduction medications. One important reason is that
most of these medications either did not work or were
dangerous, amphetamines and Fen-Phen being two
well-known examples of the dangers. Another reason
is the aversion to using valuable premium dollars from
all members to cover treatment of “life style” decisions
made by individual members. Not that long ago many
health plans did not cover medications for smoking
cessation or provide any coverage for substance abuse
treatment, whereas coverage is currently available in
most plans. It is generally accepted today that many
“life style” choices may include a genetic propensity
toward the habit or addiction, and discontinuing the
behavior may not be simply a matter of choice. A third
argument is the perception that weight reduction is
most commonly done for the reason of appearance,
not to treat a disease. The articles in this supplement
show that for many individuals the presence of an
increased body mass index and waist circumference is
a problem beyond appearance and is associated with a
cluster of one or more risk factors for future diabetes
and cardiovascular disease. To help physicians combat
the increasing prevalence of obesity with associated
increases in diabetes and cardiovascular disease, man-
aged care organizations should reexamine their beneﬁt
designs around the treatment of obesity. Increasing
coverage of wellness programs, nutritional counseling
and weight reduction programs, and safe and effective
medications for weight reduction should be consid-
ered. Managed care organizations have the tools to
insure only the appropriate risk population receives
treatment for their obesity and associated cardiomet-
abolic risk factors. A blanket exclusion of weight
reduction services and medications may no longer be
in the best interest of managed care organizations or
their members.
